These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34439083)

  • 61. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
    Del Poeta G; Ammatuna E; Lavorgna S; Capelli G; Zaza S; Luciano F; Ottone T; Del Principe MI; Buccisano F; Maurillo L; Panetta P; de Fabritiis P; Stasi R; Venditti A; Amadori S; Lo Coco F
    Br J Haematol; 2010 May; 149(3):383-7. PubMed ID: 20148885
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Exploration of ETV6::ABL1-positive AML with concurrent NPM1 and FLT3-ITD mutations.
    Li HD; Chen SS; Ding J; Zhang CL; Qiu HY; Xia XX; Yang J; Wang XR
    Ann Hematol; 2024 Aug; ():. PubMed ID: 39105739
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
    Guenounou S; Delabesse E; Récher C
    Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
    Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
    Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
    [TBL] [Abstract][Full Text] [Related]  

  • 67. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
    Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.
    Rosenberg MW; Watanabe-Smith K; Tyner JW; Tognon CE; Druker BJ; Borate U
    Oncotarget; 2020 Jul; 11(29):2807-2818. PubMed ID: 32754299
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
    How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
    Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
    Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
    Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.
    Schmid C; Labopin M; Socié G; Daguindau E; Volin L; Huynh A; Bourhis JH; Milpied N; Cornelissen J; Chevallier P; Maertens J; Jindra P; Blaise D; Lenhoff S; Ifrah N; Baron F; Ciceri F; Gorin C; Savani B; Giebel S; Polge E; Esteve J; Nagler A; Mohty M;
    Blood; 2015 Oct; 126(17):2062-9. PubMed ID: 26351297
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeted therapy in NPM1-mutated AML: Knowns and unknowns.
    Wang R; Xu P; Chang LL; Zhang SZ; Zhu HH
    Front Oncol; 2022; 12():972606. PubMed ID: 36237321
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    Hemsing AL; Rye KP; Hatfield KJ; Reikvam H
    Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009428
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth.
    Coleman DJL; Keane P; Luque-Martin R; Chin PS; Blair H; Ames L; Kellaway SG; Griffin J; Holmes E; Potluri S; Assi SA; Bushweller J; Heidenreich O; Cockerill PN; Bonifer C
    bioRxiv; 2023 Jul; ():. PubMed ID: 37503022
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mutations in AML with a normal karyotype: NPM1 and FLT3-ITD, ready to use as a key prognosticator?
    Kim HJ
    Korean J Hematol; 2010 Jun; 45(2):79-80. PubMed ID: 21120181
    [No Abstract]   [Full Text] [Related]  

  • 76. Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies.
    Singh H; Lane AA; Correll M; Przychodzen B; Sykes DB; Stone RM; Ballen KK; Amrein PC; Maciejewski J; Attar EC
    Blood Cancer J; 2013 May; 3(5):e117. PubMed ID: 23708642
    [No Abstract]   [Full Text] [Related]  

  • 77. Author Correction: A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing.
    Petti AA; Williams SR; Miller CA; Fiddes IT; Srivatsan SN; Chen DY; Fronick CC; Fulton RS; Church DM; Ley TJ
    Nat Commun; 2022 Jul; 13(1):4216. PubMed ID: 35864110
    [No Abstract]   [Full Text] [Related]  

  • 78. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification.
    van der Werf I; Wojtuszkiewicz A; Meggendorfer M; Hutter S; Baer C; Heymans M; Valk PJM; Kern W; Haferlach C; Janssen JJWM; Ossenkoppele GJ; Cloos J; Haferlach T
    Blood Adv; 2021 Sep; 5(17):3254-3265. PubMed ID: 34448812
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine.
    Sun J; Ning S; Feng R; Li J; Wang T; Xing B; Zhu X; Zhao Y; Pei L; Liu H
    Anticancer Drugs; 2022 Jan; 33(1):e813-e817. PubMed ID: 34459465
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
    Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.